MEDICLIN increases consolidated sales and operating result in the first
quarter of 2024

EQS-News: MEDICLIN AG / Key word(s): Quarterly / Interim Statement
MEDICLIN increases consolidated sales and operating result in the first
quarter of 2024

02.05.2024 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Offenburg, 2 May 2024
MEDICLIN increases consolidated sales and operating result in the first
quarter of 2024

  * MEDICLIN increases its consolidated sales for the first quarter of 2024
    by 4.9% to EUR 185.4 million

  * Group EBIT of EUR 4.1 million significantly higher than in the same
    period of the previous year (EUR -1.7 million)

  * Capacity utilisation rate up on previous year at 85.1 % (3M 2023: 82.4
    %)

Offenburg, 2 May 2024: In the first three months of 2024, MEDICLIN
Aktiengesellschaft (MEDICLIN) generated consolidated sales of EUR 185.4
million, which is EUR 8.7 million or 4.9 % more than in the first quarter of
2023. Consolidated operating profit improved by EUR 5.8 million from EUR
-1.7 million to EUR 4.1 million compared to the same period of the previous
year. Overall capacity utilisation of 85.1% (3M 2023: 82.4%) underlines a
solid first quarter.

"We are focussing on rehabilitation and want to develop and offer ambulatory
solutions. The changes in our portfolio underline this. The sale of the
former MEDICLIN Herzzentrum Coswig was completed on 1 April with the
transfer of operations to the new owner," says Dr Joachim Ramming, CEO of
MEDICLIN, adding: "On 5 April, we signed the purchase agreement for the
Reha-Klinik am Sendesaal in Bremen, thereby highlighting our core
competence, rehabilitation."

Tino Fritz, CFO of MEDICLIN, comments: "MEDICLIN ended the first quarter of
2024 with a solid result. Overall capacity utilisation is not yet in line
with our target, but is stable at a satisfactory level. The first quarter is
a seasonally weak quarter, which is why we are positive about the remaining
quarters."

Sales and earnings performance of the segments

In the post-acute segment, sales increased by 6.4% to EUR 112.7 million (3M
2023: EUR 105.9 million). At EUR 5.9 million, segment operating profit was EUR 3.0
million higher than in the same period of the previous year (3M 2023: EUR 2.9
million). The cost of materials ratio remained unchanged at 22.3%. At EUR 25.1
million, the absolute cost of materials was 6.5% higher than in the previous
year (3M 2023: EUR 23.6 million). Personnel expenses increased by EUR 1.4
million or 2.3% to EUR 61.7 million compared to the same quarter of the
previous year. The personnel expenses ratio fell to 54.8% (3M 2023: 56.9%).

The acute segment reported an increase in segment sales of EUR 0.6 million
or
0.9%. The segment operating profit was EUR -1.3 million after EUR -4.7
million in the first quarter of 2023. At EUR 19.6 million, the cost of
materials was almost unchanged from the same quarter of the previous year
(3M 2023: EUR 19.8 million). The cost of materials ratio declined slightly
to 29.8% (3M 2023: 30.4%). Personnel expenses totalled EUR 39.7 million and
were therefore 1.3% lower than in the first three months of 2023 (3M 2023: EUR
40.2 million). The personnel expenses ratio was 60.4% after 61.8% in the
same period of the previous year.

Sales in the Other Activities and Reconciliation segment totalled EUR 7.0
million, up EUR 1.3 million or 25.2% on the previous year. The nursing care
business area contributed sales of EUR 5.9 million to this figure, which
corresponds to an increase of 18.5% compared to the previous year (3M 2023:
EUR 4.9 million). At -0.5 million euros, the segment operating profit was
below the previous year's result of 0.1 million euros.

Outlook and news

The transfer of operations of the former MEDICLIN Heart Centre Coswig to the
new owner, Johannesstift Diakonie, took place on 1 April. The transfer of
operations of our new rehabilitation clinic at the Sendesaal in Bremen was
completed on 1 May. As a result, the Management Board adjusted the guidance
stated in the 2023 annual report and published it in the interim report for
the first quarter of 2024.

The interim report as at 31 March 2024 is available from today at
www.mediclin.de in German and English.

For more information:

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg
Germany

Investor Relations
Ender Gülcan
Phone +49 781/488-326
ender.guelcan@mediclin.de


Public Relations
Dr Janina Lossen
Phone: 0781/488-180
janina.lossen@mediclin.de


www.mediclin.de



About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 32 clinics, six care facilities and ten medical care
centers. The Group has around 8,300 beds/care places and employs around
10,000 people. In a strong network, MEDICLIN offers the patient integrative
care from the first visit to the doctor through the operation and subsequent
rehabilitation to outpatient aftercare. Doctors, therapists and nurses work
together in a carefully coordinated manner. MEDICLIN designs the care and
support of people in need of care according to their individual needs and
personal needs.

MEDICLIN a company of the Asklepios Group


---------------------------------------------------------------------------

02.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        MEDICLIN AG
                   Okenstraße 27
                   77652 Offenburg
                   Germany
   Phone:          +49 (0)781 488-326
   Fax:            +49 (0)781 488-184
   E-mail:         ender.guelcan@mediclin.de
   Internet:       www.mediclin.de
   ISIN:           DE0006595101
   WKN:            659510
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1894449

End of News EQS News Service
---------------------------------------------------------------------------

1894449 02.05.2024 CET/CEST